Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Multiple myeloma 'jab' gains license

  • 1 Comment

The multiple myeloma drug bortezomib (Velcade) has been licensed for subcutaneous administration.

The proteasome inhibitor was initially licensed only for intravenous use.

The European Commission’s decision to approve subcutaneous in addition to intravenous administration was based on results from a trial involving 222 patients with relapsed multiple myeloma.

The results, published in the Lancet Oncology in May 2011, showed subcutaneous bortezomib was non-inferior in terms of efficacy to intravenous administration, but had an improved safety profile.

Manufacturer Janssen said subcutaneous injections were administered at 2.5 mg/mL to limit the volume injected.

This was a higher concentration than used intravenously, which meant the same amount of medication was delivered through a smaller volume.

Charlotte Bloodworth, myeloma and lymphoma clinical nurse specialist at the University Hospital of Wales in Cardiff, said: “Subcutaneous administration of Velcade will be much easier and more convenient for both nurses and patients alike.

“Myeloma patients can have quite difficult veins to access, and subcutaneous administration completely removes the necessity to cannulate, which can be time-consuming for us, and painful for them.”

She added: “There is a lot less wastage with subcutaneous administration too, as there is no need to use expensive additional equipment such as giving sets. I think it will now become the preferred route of administration for nurses.”

  • 1 Comment

Readers' comments (1)

  • Anything which is more comfortable for the patient and easier to admininster, with same effect, MUST be a good idea!

    Unsuitable or offensive? Report this comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.

Related Jobs